Gefitinib Package Insert

A Phase I Dose-escalation Study Of LY2875358, A Bivalent MET ...
To gefitinib could be managed by dosing interruption (up to 14 days), followed by reinstatement of the 250 mg daily dose at the discretion of the investigator and according to the Japanese package insert [18]. Clinical assessments Adverse events were graded using the NCI CTCAE version 4.02. Tumor response was assessed by RECIST version 1.1 ... View Document

Tarceva (erlotinib) Label - Food And Drug Administration
[see Clinical Studies (14.4) or the gemcitabine package insert]. Treatment should continue until disease progression or unacceptable toxicity occurs. 2.3 . Dose Modifications . In patients who develop an acute onset of new or progressive pulmonary symptoms, such as dyspnea, cough or fever, treatment wit h TARCEVA should be ... Access Content

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
Hepatic impairment Patients with moderate to severe hepatic impairment (Child-Pugh B or C) due to cirrhosis have increased plasma concentrations of gefitinib. ... Return Document

HIGHLIGHTS OF PRESCRIBING INFORMATION ...
2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Ovarian Cancer GEMZAR®in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ... Access Content

Package Leaflet: Information For The Patient IRESSA 250
Package leaflet: Information for the patient IRESSA 250 mg film-coated tablets gefitinib Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. ... Retrieve Here

Review Of Newly Approved Oncologic Therapies: 2014–2015
Pembrolizumab was approved in September 2014 for treatment of unresectable metastatic melanoma. Which of the following adverse effects is a potential immune-mediated side ... Document Retrieval

HIGHLIGHTS OF PRESCRIBING INFORMATION Proteinuria: Monitor ...
Refer to everolimus prescribing information for recommended everolimus dosing information. 2.4 Recommended Dosage for Hepatocellular Carcinoma (HCC) The recommended dosage of LENVIMA is based on actual body weight: • 12 mg for patients greater than or equal to 60 kg or • 8 mg for patients less than 60 kg. ... View Full Source

FDA Briefing Document Oncologic Drugs Advisory Committee ...
The attached package contains background information prepared by the Food and Drug Administration (FDA) for the panel members of the advisory committee. ... Retrieve Document

US-22058 HIGHLIGHTS PRESCRIBING INFORMATION ...
Taken with food. Please refer to the Full Prescribing Information for palbociclib. When FASLODEX is used in combination with abemaciclib, the recommended dose . of abemaciclib is 150 mg orally, twice daily. Abemaciclib may be taken with or without food. Please refer to the Full Prescribing Information for abemaciclib. ... Access Full Source

1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CYRAMZAsafely and effectively. See full prescribing information ... Read Document

ToposarTM - Pfizer
TOPOSAR is contraindicated in patients who have demonstrated a previous hypersensitivity to it. WARNINGS Patients being treated with TOPOSAR must be frequently observed for myelosuppression both during and after therapy. Dose-limiting bone marrow suppression is the most significant toxicity associated with etoposide therapy. ... Fetch Here

HIGHLIGHTS OF PRESCRIBING INFORMATION QT Interval ...
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE ZYKADIA® is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test ... Retrieve Document

HIGHLIGHTS OF PRESCRIBING INFORMATION These Highlights Do Not ...
US-23584. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TAGRISSO . safely and effectively. ... Document Viewer

Denileukin Diftitox - Wikipedia
Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. Denileukin diftitox could bind to Interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells. ... Read Article

HIGHLIGHTS OF PRESCRIBING INFORMATION These Highlights Do Not ...
Tablets containing sorafenib tosylate (274 mg) equivalent to 200 mg of sorafenib. NEXAVAR tablets are round, biconvex, red film-coated tablets, debossed with the “Bayer cross” on one side and “200” on the other side. ... Doc Viewer

Reference ID: 4177271 - Genentech
3 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Unresectable or Metastatic Melanoma ZELBORAF® is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ... Fetch Here

Advanced Non-small Cell Lung Cancer With TKI And PD-1 Drugs
Documentation results of genetic testing where required per drug package insert. Documentation results of all required laboratory values and patient-specific information (e.g., weight, ALT/AST, and creatinine kinase) when recommended or required per drug package gefitinib, or pemetrexed for ... Read Document

HIGHLIGHTS OF PRESCRIBING INFORMATION Bullous And Exfoliative ...
FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 EGFR Mutation-Positive, Metastatic Non-Small Cell Lung Cancer GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer ... Read Document

Esomeprazole - Wikipedia
Esomeprazole, sold under the brand names Nexium among others, is a proton-pump inhibitor which reduces stomach acid. It is used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. ... Read Article

HIGHLIGHTS OF PRESCRIBING INFORMATION With A Fluoropyrimidine ...
3 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Melanoma KEYTRUDA®(pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma [see Clinical Studies (14.1)]. 1.2 Non-Small Cell Lung Cancer ... Read Full Source